抗癌药物S-1引起眼部并发症的预测因素。

Predictive factors for ocular complications caused by anticancer drug S-1.

作者信息

Yamada Rika, Sotozono Chie, Nakamura Takahiro, Nishida Akihiro, Nakanishi Shinya, Hirabatake Masaki, Tsuji Akihito, Kurimoto Yasuo

机构信息

Department of Ophthalmology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.

Department of Ophthalmology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.

出版信息

Jpn J Ophthalmol. 2016 Mar;60(2):63-71. doi: 10.1007/s10384-015-0421-1. Epub 2016 Feb 3.

DOI:10.1007/s10384-015-0421-1

PMID:26842341

Abstract

PURPOSE

To identify predictive factors for ocular complications caused by the anticancer drug S-1.

METHODS

A questionnaire was administered to 39 patients who underwent S-1 chemotherapy at Kobe City Medical Center General Hospital, with the aim to determine whether these patients were aware of the ocular complications caused by S-1. Cognition rate was determined. The 26 patients who requested opthalmological examination for further evaluation studied further and classified into two groups-those who had developed corneal epithelial complications, conjunctival injection or chemosis, or lacrimal duct blockages (referred to as the positive group) and those without these findings (referred to as the negative group). Predictive factors, such as age, sex, total administration days, total dose, presence or absence of anticancer drug pretreatment, and single-drug or combination-drug therapy, were investigated and compared between groups.

RESULTS

Of the 39 patients who completed the questionnaire, ten were aware of the potential for ocular complications due to S-1 chemotherapy (cognition rate 25.6 %). Of the 26 patients who had requested opthalmological examination and entered into the study, 13 (26 eyes) were classified into the positive group, with corneal complications observed in 15 eyes (57.7 %), conjunctivitis in 26 eyes (100 %), and lacrimal duct blockage in 14 eyes (53.8 %). Cognition rate in the 13 patients in the positive group and the 13 patients in the negative group was 38.5 % (5 patients) and 7.7 % (1 patient), respectively. Patient age was significantly different between the two groups, with the patients in the positive group being significantly older than those in the negative group (mean age ± standard deviation: 71.6 ± 6.8 vs. 63.5 ± 7.3 years, respectively; P = 0.0077, Student's t test). No other significant predictive factors were detected.

CONCLUSION

Older patients were at greater risk of S-1-related ocular complications, but these complications were not associated with total administration days or total dose.

摘要

目的

确定抗癌药物S-1所致眼部并发症的预测因素。

方法

对在神户市立医疗中心总医院接受S-1化疗的39例患者进行问卷调查，以确定这些患者是否知晓S-1所致的眼部并发症。计算认知率。对要求进行眼科检查以进一步评估的26例患者进行进一步研究，并分为两组，即出现角膜上皮并发症、结膜充血或水肿、或泪道阻塞的患者（称为阳性组）和未出现这些表现的患者（称为阴性组）。调查并比较两组间的预测因素，如年龄、性别、总给药天数、总剂量、是否有抗癌药物预处理以及单药或联合用药治疗。

结果

在完成问卷调查的39例患者中，10例知晓S-1化疗可能导致眼部并发症（认知率25.6%）。在要求进行眼科检查并纳入研究的26例患者中，13例（26只眼）被分为阳性组，其中15只眼（57.7%）出现角膜并发症，26只眼（100%）出现结膜炎，14只眼（53.8%）出现泪道阻塞。阳性组的13例患者和阴性组的13例患者的认知率分别为38.5%（5例）和7.7%（1例）。两组患者年龄差异有统计学意义，阳性组患者年龄显著大于阴性组（平均年龄±标准差：分别为71.6±6.8岁和63.5±7.3岁；P = 0.0077，Student t检验）。未检测到其他显著的预测因素。